lixivaptan

Palladio bags $20 million Series B to topple a problematic kidney disease drug
Endpoints
Fri, 09/25/20 - 10:33 am
Palladio Biosciences
autosomal dominant polycystic kidney disease
kidney disease
lixivaptan
Otsuka
Samsca
Cornerstone Therapeutics says FDA advisers recommend against approving its drug lixivaptan
Yahoo/AP
Thu, 09/13/12 - 04:10 pm
Cornerstone Therapeutics
FDA
advisory panel
hyponatremia
lixivaptan
Is This Drug Taking on Water?
Motley Fool
Thu, 09/13/12 - 10:08 am
lixivaptan
Cornerstone Therapeutics
Gilead, Salix, Peregrine, Navidea Approach Key Dates In September
Minyanville
Tue, 09/4/12 - 12:27 pm
Gilead
Salix
Peregrine Pharmaceuticals
Navidea Biopharmaceuticals
Crofelemer
tobramycin
Lymphoseek
bavituximab
Truvada
Eylea
Regeneron
lixivaptan
Cornerstone Therapeutics